Eikon Therapeutics Appoints Ching-Pin Chang As Executive VP & Chief Scientific Officer

Eikon Therapeutics (EIKN) presented clinical trial data for EIK1001 combined with pembrolizumab and chemotherapy in advanced non-small cell lung cancer patients. The trial showed objective response rates of 72.4% in squamous and 55.6% in non-squamous cohorts. The company plans a Phase 2/3 trial with an interim analysis expected in late 2027.

Eikon Therapeutics reported updated trial results for EIK1001 in NSCLC, showing a 63.1% response rate and 89.2% disease control rate. The squamous cohort had a 72.4% response rate. Grade 3 or higher adverse events occurred in 48.6% of patients. The company expects interim analysis from the Phase 2/3 trial in late 2027.

Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress • TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable e

Eikon Therapeutics (EIKN) reported 63.1% ORR in NSCLC combo trial with EIK1001, pembrolizumab, and chemo. Squamous cohort showed 72.4% ORR, 100% DCR, and 12.9-month median DOR. Phase 2/3 trial ongoing, with interim analysis expected in 2H 2027. Safety profile was consistent with standard of care.

Eikon Therapeutics (EIKN) presented updated data for EIK1001 at ESMO 2026, showing 72% ORR and 100% DCR in squamous NSCLC patients. The trial combines EIK1001 with pembrolizumab and chemotherapy, with a median response duration of 12.9 months. Eikon is conducting a Phase 2/3 trial (TeLuRide-008) with interim analysis expected in 2H 2027.

Eikon Therapeutics (EIKN) presented clinical data for its EIK1003, EIK1004, and EIK1005 programs, showing antitumor activity and manageable safety profiles. EIK1003 monotherapy had a 14.3% overall response rate, higher among PARP-inhibitor-naïve participants. Combinations with abiraterone and paclitaxel showed preliminary activity. EIK1004 had a 12.1% response rate with minimal severe toxicities. EIK1005 monotherapy resulted in stable disease for most participants.